To investigate the diagnostic value or information feedback of tumor markers combined with F-FDG PET/CT computer imaging on recurrence and metastasis of non-small cell lung cancer (NSCLC). METHODS: From January 2013 to December 2017, 95 NSCLC patients undergoing systemic F-FDG PET/CT computer imaging examination at the PET/CT computer imaging center of Mudanjiang Medical University had been enrolled. Typically, the interval between the completion of treatment and PET/CT computer imaging examination should be at least three months. Besides, all patients had undergone serum CEA monitoring before and after F-FDG PET/CT computer imaging, and 70 of them had received CYFRA21-1 test at the same time. Tumor markers were examined with PET/CT at intervals of less than one week, and all the feedback results were compared with clinical follow-up results or final pathology. Additionally, all the enrolled patients were followed up for 6-12 months. RESULTS: The sensitivity, accuracy, specificity, positive predictive value and negative predictive value of F-FDGPET/CT information feedback in evaluating recurrence or metastasis after NSCLC treatment were superior to those of common tumor markers, and the differences were statistically significant (P<0.05). Those of F-FDG PET/CT computer imaging combined with tumor marker examination for the recurrence and/or metastasis after NSCLC treatment were remarkably higher than those of either individual examination, and the accuracy difference of information feedback had significant statistical significance (P<0.05). Clearly, the diagnosis using tumor markers was correlated with that by F-FDG PET/CT imaging, and the correlation coefficient was r=0.63. Moreover, serum CEA was grouped at different levels, and the positive rate and accuracy of F-FDG PET/CT computer imaging diagnosis were increased with the increase in CEA level. 8 patients had received F-FDG PET/CT dual-phase examination, among them, 4 were diagnosed with recurrence or metastasis after MSCLC treatment, and all of them had been detected.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jiph.2019.06.027 | DOI Listing |
Indian J Urol
January 2025
Department of Urology, Apollo Hospital, Chennai, Tamil Nadu, India.
Introduction: Gallium-68 prostate-specific membrane antigen positron emission tomography (Ga-PSMA PET) is being increasingly used in patients with prostate cancer (PCa) for the staging and detection of lymph node (LN) metastases, despite a lack of prospective, validated evidence. We aimed to investigate the relationship between the PSMA PET findings (maximum standardized uptake [SUV] value) and the final histopathology results (Gleason Grade [GG], and LN positivity) in patients undergoing radical prostatectomy.
Methods: This is a single centre, prospective, observational study of 63 consecutive eligible patients treated at a tertiary care centre in India.
BMC Med Imaging
January 2025
Department of Pathology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: To evaluate the staging performance of positron emission tomography/magnetic resonance imaging (PET/MRI) for confirmed esophageal cancer based on the TNM classification system as well as compare it to other alternative modalities (e.g., endoscopic ultrasonography (EUS), computed tomography (CT), MRI, and PET/CT) in a full head-to-head manner.
View Article and Find Full Text PDFClin Exp Metastasis
January 2025
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Oligorecurrent prostate cancer (PCa) can be treated with metastasis-directed therapy (MDT), which may be performed using radioguided surgery (RGS) as an experimental approach. These procedures have shown promising outcomes, largely due to the high lesion detection rate of positron emission tomography/computed tomography (PET/CT). We present a case series of patients who underwent RGS following robot-assisted radical prostatectomy (RARP).
View Article and Find Full Text PDFNucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351 Republic of Korea.
Abstract: This guideline outlines the use of F-fluoro-2-deoxyglucose positron emission tomography / computed tomography for the diagnosis and management of infectious and inflammatory diseases. It provides detailed recommendations for healthcare providers on patient preparation, imaging procedures, and the interpretation of results. Adapted from international standards and tailored to local clinical practices, the guideline emphasizes safety, quality control, and effective use of the technology in various conditions, including spinal infections, diabetic foot, osteomyelitis, vasculitis, and cardiac inflammation.
View Article and Find Full Text PDFNucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351 Republic of Korea.
This guideline outlines the use of 3,4-dihydroxy-6-F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on international standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effective application of 3,4-dihydroxy-6-F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!